ATRA - Company ID 0001604464
The table below shows Atara Biotherapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$3.07M | -$28.14M | -$29.61M | -$38.43M | -$84.53M | -$65.70M |
| Capital expenditure | - | $0.00 | $127.00K | $399.00K | $2.60M | $2.20M |
| Investing cash flow | $0.00 | $17.20M | $14.72M | -$6.01M | $60.22M | $13.50M |
| Dividends paid | - | - | - | - |
Atara Biotherapeutics, Inc. reported operating cash flow of -$50.94M for fiscal year 2025. That is up 25.9% from -$68.72M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$60.02M (FY 2016) to -$50.94M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $2.95M | -$250.00K | $24.14M | $235.00K | $19.85M | $2.89M |